J B CHEMICALS AND PHARMA

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange that August 31, 2011 has been fixed as Record Date to ascertain eligibility of the members of the company to receive the Special Interim Dividend declared by the board of directors.

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 19, 2011, titled "J.B.Chemicals declares handsome onetime special dividend".

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange that the board of directors of the company at its meeting held on August 19, 2011, has declared Special Interim Dividend of Rs.40 (Rupees Forty) per equity share of face value of Rs. 2 to reward the shareholders consequent to sale of the Russia-CIS OTC business.The dividend will be paid/dispatched on September 8, 2011.The payment of this Special Interim Dividend together with dividend distribution tax will absorb Rs. 393.78 crores.

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange that the compensation committee of the board of directors of the Company has, on August 12, 2011, issued and allotted 42,925 equity shares of face value of Rs. 2 each (2,750 shares at a premium of Rs. 61 per share, 35,150 shares at a premium of Rs. 82 per share and 5,025 shares at a premium of Rs. 93 per share) to certain employees against the exercise of options granted to them pursuant to Employees Stock Option Scheme of the Company. The issued and paid up capital has thus gone up from 8,46,61 875 equity shares of Rs. 2 each to

Jb Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of Notice issued to the shareholders of the Company in relation to ordinary resolution proposed to be passed under section 293 (1) (a) of the Companies Act, 1956 through postal ballot for the sale of company's Russia-CIS Rx business undertaking to Dr. Reddy's Laboratories Limited.

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 29, 2011, issued by the Company on the unaudited financial results for the quarter ended on June 30, 2011.

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange the Standalone Financial Results for the period ended June 30,2011.

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange regarding the Outcome of the Annual General Meeting of the Company held on July 25, 2011.

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 22, 2011, titled "Jb Chemicals & Pharmaceuticals Limited to sell its Russia-CIS Rx Business to Dr.Reddy's Laboratories Limited, Hyderabad"

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 14, 2011, titled "J.B. Chemicals announces completion of its transaction of Sale of Russia-CIS OTC Business to Cilag GmbH International"

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange regarding the outcome of postal ballot.

Jb Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of the Notice of the Annual General Meeting of the Members of the company to be held on July 25, 2011.

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange that the Compensation Committee of the Board of Directors of the Company has, on July 01, 2011, issued and allotted 35,550 equity shares of face value of Rs.2/- each (9,625 shares at a premium of Rs. 61 per share, 11,675 shares at a premium of Rs.82 per share and 14,250 shares at a premium of Rs.93 per share) to certain employees against the exercise of options granted to them pursuant to Employees Stock Option Scheme of the company. The issued and paid up capital has thus gone up from to 8,46,26,325 equity shares of Rs. 2 each

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated June 30, 2011, titled "J.B.Chemicals launches a New Domestic Division".

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the Compensation Committee of the Board of Directors of the Company has, on June 10, 2011, issued and allotted 37,250 equity shares of face value of Rs.2/- each (2,875 shares at a premium of Rs. 61 per share, 13,625 shares at a premium of Rs.82 per share and 20,750 shares at a premium of Rs.93 per share) to certain employees against the exercise of options granted to them pursuant to Employees Stock Option Scheme of the company. The issued and paid up capital has thus gone up from to 8,45,89,075 equity shares of Rs. 2 each

D.D.Chopra has submitted to the Exchange a copy of disclosure under Regulation 13(4) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Jb Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of disclosure under Regulation 13(4) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Jb Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of Notice issued to the shareholders of the Company in relation to ordinary resolution proposed to be passed under section 293 (1) (a) of the Companies Act, 1956 through postal ballot for the sale of company's Russia / CIS OTC business undertaking to Cilag GmbH International.

Jb Chemicals & Pharmaceuticals Limited has submitted to the Exchange brief details of Annual Accounts for the year ended on March 31, 2011.

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange that the Company has decided to close the Register of Member and Share Transfer Books from July 18, 2011 to July 25, 2011 (both days inclusive) for the purpose of Annual General Meeting and Declaration of Dividend.

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 23, 2011 has approved sale of the company's Russia/CIS OTC business to Cilag GmbH International.Further the Company has submitted to the exchange a copy of release dated May 23, 2011, titled "J.B.Chemicals & Pharmaceuticals Limited to sell its Russia/CIS Over-The Counter Business to Cilag GmbH International".

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended March 31,2011.

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 23, 2011 have recommended dividend @ Rs. 2.00 (100%) per equity share of face value of Rs.2/-, for the financial year ended 2010-11. This together with dividend tax would absorb Rs. 1,966.23 lacs. The dividend if declared, will be paid/ despatched on August 3, 2011.

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 23, 2011, titled "J.B.Chemicals declares good set of numbers for 2010-11".

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the Compensation Committee of the Board of Directors of the Company has, on May 03, 2011, issued and allotted 72,250 equity shares of face value of Rs.2/- each (24,600 shares at a premium of Rs. 61 per share, 26,550 shares at a premium of Rs.82 per share and 21,100 shares at a premium of Rs.93 per share) to certain employees against the exercise of options granted to them pursuant to Employees Stock Option Scheme of the company. The issued and paid up capital has thus gone up from to 8,45,16,825 equity shares of Rs. 2 each

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange the Standalone Financial Results for the period ended December 31,2010.

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 13, 2011, titled "J.B.Chemicals reports robust profits in Q3".

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange that the compensation committee of the board of directors of the Company has, on December 02, 2010, issued and allotted 57,825 equity shares of face value of Rs.2/- each (9,575 shares at a premium of Rs. 61 per share, 46,250 shares at a premium of Rs.82 per share and 2,000 shares at a premium of Rs.93 per share) to certain employees against the exercise of options granted to them pursuant to Employees Stock Option Scheme of the company. The issued and paid up capital has thus gone up from to 8,44,38,226 equity shares of Rs. 2 ea

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a Press Release dated December 02, 2010, titled " J.B.Chemicals receives US FDA approval for Diclofenac Sodium Tablets".

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 26, 2010, titled "J.B. Chemicals continues growth march in Q2".

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange the Standalone Financial Results for the period ended September 30,2010.

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange that the compensation committee of the board of directors of the Company has, on September 28, 2010, issued and allotted 42,025 equity shares of face value of Rs.2/- each of (29,150 shares at a premium of Rs. 61 per share, and 12,375 shares at a premium of Rs. 82 per share and 500 shares at a premium of Rs. 93 per share) to certain employees against the exercise of options granted to them pursuant to Employees Stock Option Scheme of the company. The issued and paid up capital has thus gone up from to 8,43,96,201 equity shares of

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange that the Compensation Committee of the Board of Directors of the Company has, on August 10, 2010 issued and allotted 27,075 equity shares of face value of Rs. 2 each (15,825 shares at a premium of Rs.61 per share and 11,250 shares at a premium of Rs. 82 per share) to certain employees against the exercise of options granted to them pursuant to Employees Stock Option Scheme of the Company. The issued and paid up capital has thus gone up from to 8,43,69,125 equity shares of Rs. 2 each to 8,43,96,200 equity shares of Rs. 2 each.

Jb Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of the minutes of the Annual General Meeting of the members of the Company held on July 23, 2010.

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 29, 2010, titled "J.B.Chemicals posts healthy performance in Q1".

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange that the Board of Directors has appointed Dr. Satyanarain Agarwala as an additional director of the Company, on July 24, 2010. Further Dr. Satyanarain Agarwala was earlier appointed as an alternate director to Mr. Vishnu D. Patel. Mr. Vishnu D. Patel ceased to be a director of the Company w.e.f. July 23, 2010, being the date of last annual general meeting, as he did not seek re-election.

Jb Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of the outcome of Annual General Meeting of the Company held on July 23, 2010.

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange that the dividend for the year 2009-10, if declared at the ensuing annual general meeting scheduled on July 23, 2010, will be paid on July 30, 2010, i.e. electronic credit in case of shares held in dematerialized form will be effected on July 30, 2010 in all eligible cases and dividend cases and dividend warrants will be mailed on July 30, 2010 in rest of the cases.

Jb Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of the Notice of the Annual General Meeting of the Members of the company to be held on July 23, 2010.

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange that the Company has decided to close the Register of Member and Share Transfer Books from July 19, 2010 to July 23, 2010 (both days inclusive) for the purpose of Annual General Meeting and Declaration of Dividend.

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange that the compensation committee of the board of directors of the Company has, on May 10, 2010, issued and allotted 16,425 equity shares of face value of Rs.2/- each of the Company to various employees against exercise of options granted to them on April 01, 2004 at exercise price of Rs.63/- per share. The issued and paid up capital has thus gone up from 8,43,52,700 shares of Rs.2/- each to 8,43,69,125 equity shares of Rs.2/- each.

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 05, 2010, titled "J. B. Chemicals declares robust profits for 2009-10".

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange that the Board of Director at its meeting held on May 05, 2010 has recommended a dividend of Rs. 2 (100%) per equity share of Rs. 2. This together with dividend distribution tax will absorb Rs. 1967.62 lacs.

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange that the compensation committee of the board of directors of the company has, on April 27, 2010, issued and allotted 26,350 equity shares of face value of Rs.2/- each of the Company to various employees against exercise of options granted to them on April 01, 2004 at exercise price of Rs.63/- per share. The issued and paid up capital has thus gone up from 8,43,26,350 shares of Rs.2/- each to 8,43,52,700 equity shares of Rs.2/- each.

Jb Chemicals & Pharmaceuticals Ltd. has informed the Exchange regarding a press release, dated January 28, 2010, with respect to unaudited financial results for the quarter ended on December 31, 2009. A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/JBCHEM_PR_28012010.zip target=NEW> For more details click here.</a>

Jb Chemicals & Pharmaceuticals Ltd. has informed the Exchange regarding a press release, dated October 26, 2009, on unaudited financial results for the quarter ended on September 30, 2009. A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/JbChem_PR_26102009.zip target=NEW> For more details click here.</a>

Jb Chemicals & Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated August 28, 2009 regarding "Jb Chemicals & Pharmaceuticals Ltd. (JBCPL) announces the receipt of US FDA Approval to the it's Abbreviated New Drug Application (ANDA) for Cetirizine Hydrocholoride (anti-allergic) 5 mg. and 10 mg. Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/JBCHEMICAL_PR_28082009.zip target=NEW> For mor

Jb Chemicals & Pharmaceuticals Ltd. has submitted to the Exchange a copy of the minutes of the Annual General Meeting of the members of the Company held on July 13, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/jbchem_MAGM_31072009.zip target=NEW> For more details click here.</a>

Jb Chemicals & Pharmaceuticals Ltd. has submitted to the Exchange a copy of the press release on Unaudited Financial Results for the quarter ended on June 30, 2009. A copy of the press release be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/JBCHEMICALS_PR_22072009.zip target=NEW> For more details click here.</a>

Jb Chemicals & Pharmaceuticals Ltd. has informed the Exchange that, at the Annual General Meeting held on July 13, 2009, the members of the company have unanimously: 1) approved financial statements for the year ended on March 31, 2009 and report of the auditors and board of directors thereon; 2) approved declaration of dividend at the rate of Re.1 per equity share of face value of Rs.2; 3) approved the re-appointment of Mr. Bansidhar S. Mehta, Mr. Durgass Dass Chopra, Mr. Rajiv Mody & Mr. Bharat P. Mehta as directors of the company; and 4) re-appointed the auditors to hold office until the co